Company / Current Assets
Adaptimmune Therapeutics PLC Current Assets History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$188.2M
FY2024
5-year range
$188.2M / $415.5M
FY2020-FY2024
Trend
-9.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has declined for 3 consecutive years, from $415M in FY2021 to $188M in FY2024.
Based on SEC 10-K filings.
$188M in FY2024 with a 5-year CAGR of +9.3%.
Declined from $255M to $188M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -23.2%
- 5-Year CAGR
- +9.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- Adaptimmune Therapeutics PLC's current assets has declined for 3 consecutive years.
- 5-year CAGR of +9.3%, indicating consistent growth.
- In FY2024, current assets decreased 9.3% year-over-year.
- Peak current assets was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $188.2M | -9.3% |
| FY2023 | $207.6M | -18.7% |
| FY2022 | $255.4M | -38.5% |
| FY2021 | $415.5M | +4.3% |
| FY2020 | $398.2M | +230.4% |
| FY2019 | $120.5M | -47.9% |
| FY2018 | $231.1M | +0.4% |
| FY2017 | $230.2M | +15.8% |
| FY2016 | $198.8M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026